Baxter AG

ACTIVE

Thurgauerstrasse 130, Glattpark (Opfikon), Zürich, Switzerlandwww.baxter.chSubsidiary

Also known as:

apotheke im freihof

Part of BAXTER INTERNATIONAL INC.

Clinical Trials

14 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

14.3%

Trial Status Distribution

Active, not recruiting

100.0%

Clinical Trials

Trials sponsored by this organization (14)

Advate Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (Advate rAHF?PFM): A Phase 4 Study Comparing Two Prophylactic Regimens In Subjects With Severe Or Moderately Severe Hemophilia A. - ADVATE: A Phase IV Prophylactic Study

Active, not recruiting

Mar 200966 participants

An Open-Label Phase III Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as well as in Specified Risk Groups - Phase III Study of a H5N1 Vaccine in Adults, Elderlys, and Specified Risk Groups.

Active, not recruiting

May 20083,560 participants

AN OPEN-LABEL PHASE II STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF A BOOSTER VACCINATION WITH A HETEROLOGOUS VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE IN A HEALTHY YOUNG ADULT POPULATION (FOLLOW UP TO STUDY 810501) - INACTIVATED A/H5N1/INDONESIA/05/2005 INFLUENZA VACCINE

Active, not recruiting

Aug 2007141 participants

OPEN-LABEL PHASE IV STUDY TO INVESTIGATE THE SEROPERSISTENCE OF TICK-BORNE ENCEPHALITIS (TBE) VIRUS ANTIBODIES AFTER THE FIRST BOOSTER AND THE RESPONSE TO A SECOND BOOSTER VACCINATION WITH FSME-IMMUN 0.5ML IN ADULTS (FOLLOW UP TO STUDY 223) - TBE Seropersistence Adults

Active, not recruiting

Jul 2007

Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF PFM): A Phase 4, Prospective, Controlled, Randomized, Multi-Center Study to Compare the Efficacy and Safety of Continuous Infusion (CI) versus Intermittent Bolus Infusion (BI) in Subjects with Severe or Moderately Severe Hemophilia A Undergoing Unilateral Primary Total Knee Replacement - Advate Randomized Surgery

Phase 1

Active, not recruiting

Mar 200772 participants

Factor antihemofílico (recombinante), Método Libre de Plasma/Albúmina (rAHF-PFM): Un Estudio Multicéntrico, Aleatorizado, Controlado, Prospectivo y de Fase 4 para Comparar la Eficacia y Seguridad de la Infusión Continua (CI, por sus siglas en inglés) frente a la Infusión de Bolo Intermitente (BI, por sus siglas en Inglés) en Pacientes con Hemofilia A Grave o Moderadamente Grave sometidos a Sustitución Primaria Unilateral Total de Rodilla - Advate Randomized Surgery

Active, not recruiting

Jun 200660 participants

ADVATE ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN FREE METHOD (ADVATE rAHF PFM): A PHASE 4 STUDY COMPARING TWO PROPHYLACTIC REGIMENS IN SUBJECTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA A - Advate Prophylaxis Phase IV

Active, not recruiting

Jan 200666 participants

ADVATE ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN FREE METHOD (ADVATE rAHF PFM): A PHASE 4 STUDY COMPARING TWO PROPHYLACTIC REGIMENS IN SUBJECTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA A - Advate Prophylaxis Phase IV

Active, not recruiting

Jan 200666 participants

Approvals

Approvals by Agency

CANADA

Health Canada

Approvals

PHILIPPINES

Philippines FDA

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

Approvals

Recent Approvals

VACUNA GRIPE PANDEMICA H5N1 BAXTER

CIMA_AEMPS

2012-10-21

VACUNA GRIPE PANDEMICA H5N1 BAXTER

CIMA_AEMPS

2012-10-21

VEPACEL SUSPENSION INYECTABLE

CIMA_AEMPS

2012-10-17

ANTITHROMBIN III IMMUNO

News

No news articles found

Back to Organizations